trending Market Intelligence /marketintelligence/en/news-insights/trending/yusgyxrtupv0i4gfak8vfg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Dova Pharmaceuticals prices common stock offering

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Dova Pharmaceuticals prices common stock offering

Dova Pharmaceuticals Inc. priced its underwritten public offering of 2.5 million common shares at $32 each.

The Durham, N.C.-based company expects to raise gross proceeds of about $80 million through the offering, which is expected to close Feb. 27, subject to customary closing conditions.

Dova Pharmaceuticals, which develops drugs for platelet deficiency, granted underwriters a 30-day option to buy up to an additional 375,000 at the offering price.

J.P. Morgan Securities LLC, Jefferies LLC and Evercore Group LLC are acting as joint book-running managers for the offering.